医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

 Genetron Health Announces Strategic Collaboration with CStone

2019年12月13日 PM11:05
このエントリーをはてなブックマークに追加


 

BEIJING

Recently, Genetron Health has announced strategic collaboration with CStone Pharmaceuticals (“CStone”), providing companion diagnostic development services and clinical sample testing services for the oncological targeting pharmaceutical R&D of CStone, in order to boost efficiency of new medicine development and its approval processes.

Based on diverse testing platforms, independently researched and developed bioinformatics analysis platforms, vast databases as well as consistent and efficient innovative abilities supported by the multi-disciplinary research team, Genetron Health has registered multiple patents, including ‘One-Step Seq Method,’ and obtained NMPA approvals of various IVD devices and assays, which has led to accumulation of extensive R&D experience and registration applications with NMPA. Moreover, benefiting from its world-leading quality management system and rich clinical partnership resources, Genetron Health has established a full-cycle pharmaceutical R&D service system, which is capable of providing standardized full-chain services for its partners, consisting of multinational pharmaceutical companies, innovative pharmaceutical companies and biomedical CROs in the fields including early stage biomarker development, RWS, molecular testing for clinical trials, patient recruitment and filtering, and companion diagnostic development and commercialization.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191213005208/en/

CONTACT

Media:

Genetron Health

TAO Yuan

Email: yuan.tao@genetronhealth.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease